FPWR has once again partnered with COMBINEDBrain to collect blood and urine samples for our PWS & SYS biorepositories.
Study Purpose This open-label study will study the safety, tolerability, pharmacokinetics, and efficacy of NNZ-2591 in children with PWS ages 4 to 12 years. Study participants will receive NNZ-2591 oral solution ( a ready-to-drink strawberry-flavored liquid) twice daily for 13 weeks. Every participant will receive NNZ-2591. Participation involves 5 trial visits to the study site over the course of the study. All travel and lodging expenses will be reimbursed. Enrollment will begin with children ages 8-12. After safety and tolerability data has been reviewed, children ages 4-7 will be able to enroll.
Study Purpose Maimonides Medical Center is seeking volunteers with PWS ages 6 and up to participate in a clinical research study to see if light therapy can be used to reduce Excessive Daytime Sleepiness (EDS).
Study Purpose KITE PWS is a Phase 2 study to investigate the effects of RGH-706 in people with Prader-Willi Syndrome. This study is seeking people aged 17 years and older with Prader-Willi syndrome for participation and will evaluate an experimental oral drug that may help to reduce appetite. The study lasts 5-6 months and requires about 8 study visits.
*****THIS STUDY HAS COMPLETED ENROLLMENT***** Study Purpose This is an open-label, single-center, Phase 1 study to evaluate the PK and safety of a 10 mg single oral dose of CSTI-500, a triple monoamine reuptake inhibitor (TRI), in people with PWS. The study is looking to enroll 14 individuals between the ages of 13 and 50 years.
Study Purpose RGH-706 is a once-daily oral capsule that has been developed by Gedeon Richter for weight management. The Phase 2 study of RGH-706 will evaluate the efficacy, safety, and tolerability of RGH-706 in people with Prader-Willi syndrome and will measure changes in hyperphagia, body weight, body mass, metabolism, and clinical global impression.
Study Purpose This is a Phase 2, open-label study to investigate the effects of ARD-101 in people with Prader-Willi Syndrome. This study is looking to enroll 12 individuals between the ages of 17 and 65 years. Participants will take ARD-101 orally, twice daily for 28 days.
This study is on a voluntary pause while the company works to secure funding. Study Purpose Tesomet is a first-in-class triple monoamine re-uptake inhibitor / beta-1 blocker which is being studied as a possible treatment for hyperphagia in Prader-Willi syndrome.
Study Purpose If you are the caregiver and the parent or legal guardian of someone aged 6 to 65 years of age who has been diagnosed with Prader-Willi syndrome (PWS) and who also experiences daytime sleepiness, you and your care recipient may qualify for a 90-minute video interview that will pay you $100 for your participation.
Understanding the Pathophysiology of Schaaf-Yang Syndrome to Improve Care and Treatment Options Dr. Fleischer at Southern Illinois University School of Medicine, in conjunction with Dr. Schaaf from Heidelberg University in Germany, is conducting a study entitled, “Understanding the Pathophysiology of Schaaf-Yang Syndrome to Improve Care
